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Tamoxifen — no longer a golden standard for adjuvant  
therapy in the treatment of premenopausal patients  
with hormone-sensitive breast cancer
Renata Duchnowska
For several decades, in breast cancer patients with a luminal subtype, tamoxifen has been the main endocrine therapy 
in adjuvant setting in both pre- and postmenopausal women. However, it may be suboptimal in some premenopausal 
patients. The results of prospective, randomised studies SOFT/TEXT clearly demonstrated that the combination of 
OFS with TAM or IA is more effective than monotherapy TAM in breast cancer premenopausal women with hormone-
sensitive early breast cancer and a high risk of recurrence.
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Introduction 
Luminal breast cancer (with the expression of the oes-
trogen (ER) and/or progesterone PR receptor) makes up 
a heterogenous group of cancer with a varied clinical course 
and response to treatment. Currently there are three mo-
lecular subtypes of luminal breast cancer and the subtypes 
which are similar to them, determined on the basis of the 
reception of the steroid receptors and human epidermal 
growth factor receptor type 2 (HER2): luminal A, luminal B — 
HER2-negative and luminal B — HER2-positive [1, 2]. Within 
these subtypes there are also mutations found e.g. phospho-
inositide-3 kinase catalytic subunits p110; (PIK3CA), ESR1 or 
HER2, which can determine the response to treatment, [3–5]. 
For a few decades, hormone therapy with tamoxifen (TAM) 
has been the main method of the adjuvant treatment of the 
luminal subtype in both pre- and postmenopausal women 
[2, 6–9]. It seems, however, that the treatment might be 
suboptimal in some premenopausal patients. 
Special attention in the debate on the treatment of 
breast cancer in premenopausal women is devoted to the 
role of ovarian function suppression (OFS). The analysis, 
published in year the 2000 concerning research in this issue, 
carried out by the International Breast Cancer Study Group 
(IBCSG) showed that in patients with ER/PR expression with-
out amenorrhea with a history of previous adjuvant chemo-
therapy, the prognosis of the disease free survival (DFS) 
and overall survival, (OS) is significantly worse in the age 
subgroup below 35 years in comparison with patients older 
than 35 [10]. Some further studies also showed that apart 
from the age of the patients, the percentage of amenor-
rhea is also affected by the type of chemotherapy used: the 
regimens based on anthracyclines and taxoids more rarely 
lead to a permanent suppression of the ovarian function in 
comparison with the CMF (cyclophosphamide/methotrex-
ate/fluorouracil) regimen [11]. Moreover, it was shown that 
in patients below 35, the ER expression, in comparison with 
the lack of expression, was related to a significantly shorter 
10-year DFS (the median was 25% and 47% respectively; 
p = 0.014) and a tendency for a shorter OS; whilst in patients 
above this age, the ER expression had no influence on DFS, 
but it was connected with a significantly longer 10-year OS 
(63% and 58% respectively; p < 0.001) [12]. 
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Ovarian function suppression  
in tamoxifen therapy
In the phase-3 prospective SOFT (Suppression of Ovarian 
Function Trial) trial the premenopausal patients with ER/PR 
expression, with no history of post-surgical chemotherapy 
or in whom the oestradiol level after chemotherapy corre-
sponded to that from before the menopause, received tamox-
ifen or tamoxifen in combination with OFS (LHRH analogue 
for 5 years) [13]. Adding the OFS did not affect DFS (HR = 0.83; 
p = 0.1) in the entire group of patients, whilst the analysis 
with stratification, planned in the treatment protocol showed 
that adding OFS to tamoxifen in the subgroup of patients un-
dergoing postoperative chemotherapy was connected with 
a decrease of the relative risk of morality by as much as 36%. 
Given the fact that breast cancer is the most frequent cancer 
in women worldwide, it means a decrease of the number of 
deaths by several thousand per year. In the SOFT study, the 
adjuvant chemotherapy was more often used in patients 
below 35 years of age (94%), and, at the same time, in this 
group, treatment-related amenorrhoea was less frequent. 
The adjuvant chemotherapy was also used in the case of 
numerous (≥ 4) metastases to axillary lymph nodes and HER2 
expression. The benefits from adding OFS, in DFS and OS, 
was not observed in the subgroup of patients with good 
prognoses, similarly to another phase-3 trial (INT-0142) [14]. 
In this group of patients, TAM still remains the standard 
post-operative treatment with a possibility of extending the 
treatment to 10 years, in the light of the ATLAS and aTTom 
studies [15, 16]. On the other hand, however, in premeno-
pausal patients, the potential benefit from prolonged use 
of TAM should be interpreted with caution, as this group of 
patients made up only 13% of the total number of patients 
treated within the studies comparing varied periods of us-
ing TAM [15–17]. Irrespective of individual differences in the 
pharmacokinetics of TAM, about 20% of patients treated 
with this medication did not reach the treatment threshold 
of endoxifen — its main active metabolite [18–20].
Aromatase inhibitors in connection  
with ovarian function suppression 
The joint analysis of SOFT and TEXT (Tamoxifen and 
Exemestane Trial) studies showed that OFS (mainly LHRH an-
alogue, triptorelin administered for 5 years) in combination 
with exemestane, aromatase inhibitor (IA) in comparison 
with OFS in combination with TAM, allows an improvement 
in the 5-year DFS (91% and 87% respectively; p < 0.001), 
a decrease of the relative risk of breast cancer recurrence by 
34% (p < 0.001) and cancer dissemination by 22% (p = 0.02), 
with a similar survival period [21]. The treatment with OFS in 
combination with IA was more frequently associated with 
adverse symptoms, yet they did not cause deterioration in 
the quality of life, especially in patients with previous post-
operative chemotherapy [22]. Moreover, the intensification 
of menopausal symptoms — hot flushes or decrease of 
libido, was getting lower within the progress of time since 
the onset of treatment [22, 23]. No symptoms concerning 
the incomplete blockage of oestrogen levels in patients 
with OFS/IA were observed [24]. In the majority of cases, 
the oestradiol level was lowered below the threshold value 
for menopause: 2.72 pg/mL [24]. 
Those who question the value of the SOFT and TEXT 
trials for clinical practice, frequently refer to the result of the 
ABCSG-12 study, carried out in Austria, in which no benefits 
regarding DFS were found [25, 26]. Moreover, in some cases 
even slightly worse OS was observed in patients receiv-
ing OFS in combination with anastrozole in comparison 
with OFS in combination with TAM [25, 26]. However, in the 
ABCSG-12 study, about 70% of the subjects were in a very 
early stage — pT1N0, which confirms that, in this group, the 
use of OFS in combination with IA is completely not justified. 
Conclusions 
The results of the prospective randomised studies, SOFT/ 
/TEXT explicitly showed that the combination of OFS with TAM 
or IA is more effective than TAM in monotherapy in premeno-
pausal patients with hormone-sensitive breast cancer with 
a high risk of recurrence. This justifies a routine use of the OFS 
treatment regimes in this group of patients, with maintenance 
of the TAM therapy in the patients with good prognosis. This 
thesis was reflected in the recommendations of the St. Gallen 
2015 Conference of the European Society of Medical Oncology 
and of the National Comprehensive Cancer Network [6, 9, 28]. 
The decision concerning the choice of hormone treatment in 
breast cancer patients should be taken on an individual basis 
after a detailed discussion of the potential benefits and possible 
adverse effects of this therapy (Tab. I) [8, 29].
Table I. Hormone therapy in premenopausal patients
Premenopausal patients
Age ≤ 35 years > 35 years
Low risk of recurrence1 TAM 5–10 years2
High risk of recurrence
Approval of the adverse effects risk
Yes No Yes No
OFS/TAM lub OFS/IA3 TAM OFS/IA TAM
1pT, N, G, HER2 characteristics, OncotypeDx; 2contraindications for TAM Æ OFS (LHRH analogue) ± IA; TAM — tamoxifen; IA — aromatase inhibitors; OFS — ovarian 
suppression; 3the presentation of the adverse effects profile to the patient
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